Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets


Inhibitory receptors have been proposed to modulate the in vivo cytotoxic response against tumor targets for both spontaneous and antibody-dependent pathways1. Using a variety of syngenic and xenograft models, we demonstrate here that the inhibitory FcγRIIB molecule is a potent regulator of antibody-dependent cell-mediated cytotoxicity in vivo, modulating the activity of FcγRIII on effector cells. Although many mechanisms have been proposed to account for the anti-tumor activities of therapeutic antibodies, including extended half-life, blockade of signaling pathways, activation of apoptosis and effector-cell-mediated cytotoxicity, we show here that engagement of Fcγ receptors on effector cells is a dominant component of the in vivo activity of antibodies against tumors. Mouse monoclonal antibodies, as well as the humanized, clinically effective therapeutic agents trastuzumab (Herceptin®) and rituximab (Rituxan®), engaged both activation (FcγRIII) and inhibitory (FcγRIIB) antibody receptors on myeloid cells, thus modulating their cytotoxic potential. Mice deficient in FcγRIIB showed much more antibody-dependent cell-mediated cytotoxicity; in contrast, mice deficient in activating Fc receptors as well as antibodies engineered to disrupt Fc binding to those receptors were unable to arrest tumor growth in vivo. These results demonstrate that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Passive protection from pulmonary metastasis is increased considerably in FcγRIIB-deficient mice.
Figure 2: Anti-tumor activities of 4D5, trastuzumab and rituximab require activation Fcγ receptors.
Figure 3: Anti-breast tumor activity of 4D5 and trastuzumab is enhanced FcγRIIB-deficient mice.
Figure 4: In vitro and in vivo properties of the D255A mutant antibody.


  1. Bolland, S. & Ravetch, J.V. Inhibitory pathways triggered by ITIM-containing receptors. Adv. Immunol. 72, 149–177 (1999).

    Article  CAS  PubMed  Google Scholar 

  2. Clynes, R.A., Tekechi, Y., Moroi, Y., Houghton, A. & Ravetch, J.V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95, 652 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hudziak, R. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol. Cell Biol. 9, 1165 ( 1989);

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Taji, H. et al. Growth inhibition of CD20 positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn. J. Cancer Res. 89, 748 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Masui, H., Moroyama, T. & Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes Cancer Res. 46, 5592 (1986);

    CAS  PubMed  Google Scholar 

  6. Waldmann, T.A. Lymphokine receptors: a target for immunotherapy of lymphomas. Ann. Oncol. Supp. 13, 5, 1– 45 (1994).

    Google Scholar 

  7. Tutt, A.L. et al. Monoclonal antibody therapy of a B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161, 3176 (1998).

    CAS  PubMed  Google Scholar 

  8. Pegram, M.D. et al. Phase II study of receptor enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2.neu overexpressing metastatic breast cancer refractory to chemotherapy treatment J. Clin. Oncol. 16, 2659 (1998)

    Article  CAS  PubMed  Google Scholar 

  9. Carter, P.L. et al. Humanization of an anti-p185HER2 antibody for human cancer treatment, Proc. Natl. Acad. Sci. USA 89, 4285 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Leget, G.A. & Czuczman, M.S. Use of Rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10, 548– 551 (1998)

    Article  CAS  PubMed  Google Scholar 

  11. Kopreski, M., Lipton, A., Harvey, H.A. & Kumar, R. Growth inhibition of breast cancer cell lines by combinations of anti-p185 monoclonal antibody and cytokines. Anticancer Res. 16, 433– 436 (1996).

    CAS  PubMed  Google Scholar 

  12. Lewis, G.D. et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37, 255–263 (1993).

    Article  CAS  PubMed  Google Scholar 

  13. Shan, D., Ledbetter, J.A. & Press, O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91, 1644–1652 (1998).

    CAS  PubMed  Google Scholar 

  14. Takai, T., Li., M., Sylvestre, D., Clynes, R. & Ravetch, J.V. FcR γ chain deletion results in pleiotropic effector cell defects. Cell 76, 519– 529 (1994).

    Article  CAS  PubMed  Google Scholar 

  15. Takai, T., Ono, M, Hikida, M., Ohmori, H. & Ravetch, J.V. Augmented humoral and anaphylactic responses in Fc_RIIB deficient mice. Nature 379, 346– 349 (1996).

    Article  CAS  PubMed  Google Scholar 

  16. Funakoshi, S., Longo, D.L. & Murphy, W.J. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J. Immunother. 19, 93–101 (1996).

    Article  CAS  Google Scholar 

  17. Fan, Z., Masui, H., Altas, I. & Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Res. 53, 4322–4328 (1993)

    CAS  PubMed  Google Scholar 

  18. Baselga, J., Norton, L., Albanell, J., Kim, Y.M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825–2831 (1998).

    CAS  PubMed  Google Scholar 

  19. Liu, J., Lester, P., Builder, S. & Shine, J. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34, 10474– 10482 (1995).

    Article  CAS  PubMed  Google Scholar 

Download references


We thank D. White for his technical expertise, C. Ritter for her administrative assistance and R. Steinman and M. Nussenzweig for their comments on the manuscript. These studies were supported by grants from the National Institutes of Health, Cancer Research Institute and Genentech.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jeffrey V. Ravetch.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Clynes, R., Towers, T., Presta, L. et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6, 443–446 (2000).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing